FDA proposes new treatment approval pathway for ultra-rare diseases

The Food and Drug Administration (FDA) connected Monday announced a caller connection for flexible cause support pathway treatments addressing ultra-rare diseases. The FDA unveiled draught guidance connected a projected regulatory pathway for individualized therapies, treatments for uncommon conditions that impact a precise tiny population, with the connection specifically focusing connected genome editing and RNA-based therapies.…